Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate

Drug Profile

Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate

Alternative Names: HENO 3; MabCD3-dgA/CD7-dgA; T-Guard

Latest Information Update: 10 Feb 2016

Price : $50

At a glance

  • Originator Radboud-University-Nijmegen-Medical-Centre
  • Developer Xenikos
  • Class Drug conjugates; Immunotoxins; Lectins; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Protein synthesis inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Graft-versus-host disease

Most Recent Events

  • 10 Feb 2016 Phase-II development is ongoing in the Netherlands
  • 09 Jan 2014 Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate is available for licensing as of 09 Jan 2014. http://www.xenikos.com/
  • 03 Jan 2014 Phase-I/II clinical trials in Graft-versus-host disease (steroid-resistant) in Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top